That seems a little harsh, given that it had sales of $1.3 billion or so for the first 9 months, revenues have been increasing and Pfizer claims it is the largest selling branded glaucoma medication.
To include Martin in the same group as Mitch Gold of DNDN, Joseph Zakrzewski of AMRN, Al Mann of MNKD, and Gregory Divis Jr. of KV.A suggests to me that Feuerstein does not understand GILD as well as the thinks he does.
Market Data 
Markets 
AI
